Both CD28 ligands CD80(B7-1) and CD86(B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion
スポンサーリンク
概要
著者
-
Levine Bruce
Immune Cell Biology Program Naval Medical Research Institute
-
Ueda Yuji
Immune Cell Biology Program Naval Medical Research Institute
-
Freeman Gordon
Division Of Hematologic Malignancies Dana-farber Cancer Institute Harvard Medical School
-
JUNE Carl
Immune Cell Biology Program, Naval Medical Research Institute
-
June Carl
Immune Cell Biology Program Naval Medical Research Institute
-
HUANG Mark
Immune Cell Biology Program, Naval Medical Research Institute, and Department of Medicine, Uniformed
-
NADLER Lee
Division of Hematologic Malignancy, Dana Farber Cancer Institute
-
WARD Stephen
Department of Pharmacology, School of Pharmacy and Pharmacology, Bath University
-
Huang Mark
Immune Cell Biology Program Naval Medical Research Institute. Geo-centers Inc.
-
Nadler Lee
Division Of Hematologic Malignancy Dana Farber Cancer Institute
-
Ward Stephen
Department Of Pharmacology School Of Pharmacy And Pharmacology Bath University
関連論文
- The lgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion
- Both CD28 ligands CD80(B7-1) and CD86(B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion
- CD28 ligands CD80(B7-1) and CD86(B7-2) induce long-term autocrine growth of CD4+T cells and induce similar patterns of cytokine secretion in vitro
- Primary porcine endothelial cells express membrane-bound B7-2 (CD86) and a soluble factor that co-stimulate cyclosporin A-resistant and CD28-dependent human T cell proliferation